<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00072540</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000340176</org_study_id>
    <secondary_id>S0212</secondary_id>
    <secondary_id>U10CA037429</secondary_id>
    <nct_id>NCT00072540</nct_id>
  </id_info>
  <brief_title>S0212 Celecoxib in Treating Patients With High-Grade Squamous Intraepithelial Lesions of the Cervix</brief_title>
  <official_title>S0212: Phase IIb Randomized Study of Celecoxib in Patients With High-Grade Squamous Intraepithelial Lesions of the Cervix</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southwest Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Southwest Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the&#xD;
      development of cancer. Celecoxib may be effective in preventing cervical cancer.&#xD;
&#xD;
      PURPOSE: Randomized phase II trial to study the effectiveness of celecoxib in preventing&#xD;
      cervical cancer in patients who have high-grade squamous intraepithelial lesions of the&#xD;
      cervix.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the complete response rate in patients with high-grade squamous intraepithelial&#xD;
           lesions of the cervix treated with celecoxib vs placebo.&#xD;
&#xD;
        -  Compare the toxicity of these drugs in these patients.&#xD;
&#xD;
        -  Determine, preliminarily, the effect of celecoxib on cyclooxygenase-2 expression and&#xD;
           human papilloma virus expression in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients&#xD;
      are stratified according to high-grade squamous intraepithelial lesion status (cervical&#xD;
      intraepithelial neoplasia [CIN] 2 vs CIN 3). Patients are randomized to 1 of 2 treatment&#xD;
      arms.&#xD;
&#xD;
        -  Arm I: Patients receive oral celecoxib twice daily for 1 month.&#xD;
&#xD;
        -  Arm II: Patients receive oral placebo twice daily for 1 month. In both arms, treatment&#xD;
           repeats monthly for 3 courses in the absence of disease progression or unacceptable&#xD;
           toxicity. All patients then undergo loop electrosurgical excision procedure or cone&#xD;
           biopsy to determine response.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 100 patients (50 per treatment arm) will be accrued for this&#xD;
      study within 1-2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    drug issues&#xD;
  </why_stopped>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">0</enrollment>
  <condition>Stage 0 Cervical Cancer</condition>
  <condition>High-grade Squamous Intraepithelial Lesion</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celecoxib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>anti-cytokine therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>antiangiogenesis therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biological therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cancer prevention intervention</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>chemoprevention of cancer</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>enzyme inhibitor therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>growth factor antagonist therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed high-grade squamous intraepithelial lesions (HGSIL) of the&#xD;
             cervix&#xD;
&#xD;
          -  Cervical intraepithelial neoplasia (CIN) 2 (moderate dysplasia) OR CIN 3 (severe&#xD;
             dysplasia, carcinoma in situ)&#xD;
&#xD;
          -  Must have remaining HGSIL after biopsy&#xD;
&#xD;
          -  No suspicion of invasive cancer by colposcopy within the past 28 days&#xD;
&#xD;
          -  No invasive or preinvasive high-grade intraepithelial neoplasia by endocervical&#xD;
             curettage within the past 56 days&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Zubrod 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  SGOT and SGPT less than 2.0 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin less than 2.0 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine less than 2.0 mg/dL&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  No prior asthma, urticaria, or allergic-type reactions to aspirin or other NSAIDs&#xD;
&#xD;
          -  No allergy to sulfonamides&#xD;
&#xD;
          -  No known sensitivity to celecoxib&#xD;
&#xD;
          -  No known AIDS or HIV-associated complex&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated basal cell or&#xD;
             squamous cell skin cancer or adequately treated stage I or II cancer currently in&#xD;
             complete remission&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior pelvic radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 3 months since prior topical medications for genital condyloma&#xD;
&#xD;
          -  No prior treatment for squamous intraepithelial lesions&#xD;
&#xD;
          -  No concurrent topical medications for genital condyloma&#xD;
&#xD;
          -  No other concurrent treatment&#xD;
&#xD;
          -  No concurrent chronic (daily for more than 30 days) aspirin&#xD;
&#xD;
          -  No other concurrent nonsteroidal anti-inflammatory drugs (NSAIDs)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William R. Robinson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Harrington Cancer Center</affiliation>
  </overall_official>
  <verification_date>November 2013</verification_date>
  <study_first_submitted>November 4, 2003</study_first_submitted>
  <study_first_submitted_qc>November 4, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2003</study_first_posted>
  <last_update_submitted>November 7, 2013</last_update_submitted>
  <last_update_submitted_qc>November 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Squamous Intraepithelial Lesions of the Cervix</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Enzyme Inhibitors</mesh_term>
    <mesh_term>Mitogens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

